Nanjing Zaiming Pharmaceutical Co., Ltd.
Nanjing Zaiming Pharmaceutical Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2024-11-29 | NCT05293964 | |
| Mass Balance Clinical Trial of SIM0270 | Healthy Participants | Active, not recruiting | Phase 1 | 2024-11-27 | NCT06654791 |